Inovio receives fda feedback that data from completed phase 1/2 trial of ino-3107 can be used to submit a bla under accelerated approval program

Previously planned phase 3 trial no longer required to support biological license application (bla) submission if approved, ino-3107 could potentially revolutionize treatment options for patients with recurrent respiratory papillomatosis (rrp), a debilitating rare disease caused by human papillomavirus (hpv) ino-3107 could be the first dna medicine available in the united states and the first commercial product for inovio plymouth meeting, pa. , oct. 10, 2023 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that it has received feedback from the u.s. food and drug administration (fda) that data from its completed phase 1/2 trial of ino-3107 for the treatment of rrp could support inovio's submission of a bla for review under the fda's accelerated approval program.
INO Ratings Summary
INO Quant Ranking